Therapy duration and long-term outcomes in extra-pulmonary tuberculosis

Table 2 Multivariate analysis of factors associated with time to death for the study cohort (402 patients) with available data for the entire follow-up period*

Variable	Hazard ratio (95% CI)	P-value
Age (years)
18 – 24	Referent
25 – 34	2.75 (0.60, 12.59)	0.19
35 – 44	2.08 (0.46, 9.44)	0.34
45 – 54	2.42 (0.54, 10.85)	0.25
55 – 64	2.02 (0.42, 9.66)	0.38
65 – 74	3.71 (0.77, 17.79)	0.10
>75	7.43 (1.54, 35.93)	0.01
HIV-infected versus non-infected	2.16 (1.22, 3.83)	<0.01
Male	1.52 (1.01, 2.72)	0.04
TB disease site
Meningeal	Referent
Lymphatic	0.50 (0.27, 0.91)	0.02
Bone/joint	0.42 (0.21, 0.81)	0.01
Peritoneal	0.59 (0.27, 1.31)	0.20
Other sites	0.47 (0.23, 0.97)	0.04
Therapy duration
6-months	Referent
<6-months	2.72 (1.34, 5.50)	<0.01
7 – 10 months	1.63 (0.85, 3.12)	0.14
>10-months	1.52 (0.75, 3.10)	0.25

*Multivariate regression analysis drops patients with missing variables, so the final model comprised of 402 instead of 438 patients.